ST. PAUL, MN -- (MARKET WIRE) -- 05/15/07 -- GelStat (PINKSHEETS: GSAC) ("GelStat") is pleased to announce it will host an investor conference call on May 21, 2007, to begin at 4:15 P.M. Eastern Time.
In discussing the conference call, Tom DeSantis, Business Manager of GelStat Corporation, stated, "We are committed in providing the highest level of disclosure and communication to GelStat shareholders as well as the investment community. I am looking forward to discussing our progress over the last six months and the continued execution of our business plan over the next six months. I welcome our shareholders and the investment community and encourage them to get on the call to listen and participate."
Interested parties may hear and participate in the call by telephone. Instructions for the call are:
To hear the conference call as it takes place: Call 800-391-2548 in the United States or; Call 866-627-1646 in Canada or; Call 302-709-8328 Internationally Verbal Pass code: VT33111 To hear a recording of the call (available for 30 days following the conference call): Call 402-220-2946 Replay Pin Code: 33111#
About GelStat Corporation
GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billon each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.
The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM)Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat(TM)Sinus" and "GelStat(TM)Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers." For more information, visit www.gelstat.com.
Safe Harbor Statement under the Private Securities Litigation Act of 1995
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.
Investor Contact: Redwood Consultants, LLC 415-884-0348